US FDA approves Roche's oral treatment for advanced breast cancer
The FDA approved Roche's giredestrant with everolimus for certain adults with ESR1-mutated, advanced breast cancer. In a 207-patient study, the combination reduced the risk of disease progression or death by 62% and extended median time to progression to 10 months, versus 5.5 months with another hormone treatment plus everolimus.
1. FDA approves combination
The FDA approved Roche's giredestrant in combination with everolimus for adults with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer carrying an ESR1 mutation, after the cancer returned or worsened during or after hormone-based treatment. The approval was based on a late-stage study of 207 patients, in which the combination reduced the risk of disease progression or death by 62%.
2. Study results and test
The combination delayed cancer progression for a median of 10 months, compared with 5.5 months for another hormone treatment given with everolimus. The FDA also authorized a blood test to identify eligible patients. Common side effects included mouth sores, rash, fatigue and diarrhea.
3. Other treatment developments
Eli Lilly's Inluriyo, used with Verzenio, is another approved oral option for adults with the same breast cancer subtype and ESR1 mutation after earlier hormone therapy. Roche is separately seeking US approval for giredestrant as a post-surgery treatment for early-stage breast cancer, with a decision expected by November 30; a late-stage study showed a 30% reduction in the risk of invasive breast cancer returning or death compared with standard hormone therapy.




